A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Studiedetails
| Type carcinoma: | NSCLC zonder mutatie |
|---|---|
| Stadium: | III or metastatic IV |
| Mutatie: | |
| Lijn: | 2e |
| Site: | Erasmus MC |
| Contactgegevens: | long.oncologie@erasmusmc.nl |
| Website: |
Inclusiecriteria
Inclusion criteria:
– Histologically or cytologically confirmed diagnosis of NSCLC with locally advanced, unresectable Stage IIIB or IIIC not eligible for definitive chemoradiotherapy or metastatic (Stage IV: M1a, M1b, or M1c) disease per the American Joint Committee on Cancer (AJCC) Staging Manual, Version 8.0, and the Union for International Cancer Control (UICC) Staging System. Note: Participants with a neuroendocrine component or histology are not eligible
– PD-L1 expression on ≥1% of tumor cells based on local immunohistochemistry (IHC) testing with an assay utilizing the anti-PD-L1 monoclonal antibody clones 22C3 or SP263
– Participants who have NSCLC with known AGAs are permitted.
– Able to provide any of the following tumor tissues for biomarker analysis:
→ Archival specimen (preferably collected within 12 months after the last anticancer therapy) (see laboratory manual for details); or
→ De novo biopsy from a tumor lesion, if medically feasible.
– Participants must have received the following therapies and progressed during or relapsed after receiving their most recent prior therapy, or have been intolerant to their most recent therapy:
– Participants with no known AGAs must fulfill 1 of the following conditions:
→ Received a platinum-based combination therapy for the treatment of metastatic or recurrent disease, and unless contraindicated, a PD-(L)1 monoclonal antibody (concurrently or sequentially with platinum-based chemotherapy).
→ Experienced disease progression within 6 months of the last dose of platinum based chemotherapy in the adjuvant, neoadjuvant, or chemoradiotherapy setting and received a PD-(L)1 monoclonal antibody at any time during the course of treatment.
– Participants with known AGAs (eg, EGFR mutations, ALK translocations, or other relevant actionable mutations) must fulfill the following conditions:
→ Must have received at least 1 relevant AGA-targeted therapy if locally available and, in the opinion of the investigator, additional AGA-targeted therapy is not in the best interest of the participant
→ Received a platinum-based combination therapy for the treatment of metastatic or recurrent disease, or experienced disease progression within 6 months of the last dose of platinum-based chemotherapy in the adjuvant, neoadjuvant, or chemoradiotherapy setting.
→ May have received PD-(L)1 monoclonal antibody (concurrently or sequentially with platinum-based chemotherapy).
Exclusiecriteria
Exclusion criteria:
– History of another malignancy within 3 years before the first dose of PF-08046054, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death (eg, 5-year overall survival [OS] ≥90%), such as adequately-treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer.
– Any central nervous system (CNS) lesions, unless definitively treated with CNS-directed local therapy (surgery and/or radiotherapy). Participants with definitively treated brain metastases are eligible if they meet the following criteria:
→ The participant is on a stable dose of ≤10 mg/day of prednisone or equivalent for at least >14 days prior to randomization (if requiring steroid treatment).
→ No clinical or radiographic progression in the CNS following CNS-directed definitive radiotherapy and/or surgery.
→ Time since CNS-directed treatment is ≥28 days prior to randomization.
– Participants with a history of leptomeningeal metastasis are excluded.
– Prior treatment with an anti-PD-L1 agent (where indicated per protocol) within 5 half-lives.
– Previous receipt of an MMAE-containing agent or prior docetaxel.
Meer studies
Een overzicht van alle lopende studies binnen het longkankernetwerk. Filter op type mutatie:
TroFuse-007
1e lijn | Stadium IV | NSCLC zonder mutatie
Tiger MESO
1ste lijn | Stadium IV
SUNRAY-02
2e lijn | Stadium II en III | KRASG12C mutatie
SUNRAY-01
1e lijn | Stadium IIIB-IIIC of IV | KRASG12C mutatie
SATIN
Stadium IV
ROSETTA Lung-202
1e lijn | stadium III-IV
RASolve 301
2e lijn | IIIB of IV | RAS mutatie
PADLINK-005 (Pfizer/SGNPDL1V)
2e lijn | stadium III or metastatic IV |
OSIBOOST 2
2e lijn | Stadium IV | EGFR mutatie
OSI-SAVE
1e lijn | stadium III-IV | EGFR mutatie
OMiT IO
1ste lijn | stadium IIIb or IV |
NEOpredict-EGFR
2e lijn | Stadium IB, II of selected IIIA | EGFR mutatie
MK-2870
2e lijn | Stadium II, IIIB |
KANDLELIT-007
1e lijn | stadium III-IV | KRAS mutatie
INTerpath-014
1e lijn | stadium I |
IDeate-Lung02
2e lijn | Stadium IV |
Ensure
1ste lijn | Stadium I-IIIA
DAREON-Lung-1
1e lijn | stadium III-IV |
CUP/EAP/DAP/DRUP
Lijst van verschillende programma's
CodeBreaK 202
1e lijn | Stadium IV | KRASG12C mutatie
CARMEN-LC03
2de/3de lijn | Stadium III-IV
BNT327-003
1e lijn | stadium IV |
ARTEMIA
2e lijns | Stadium IV | KRAS en BRAF en NSCLC zonder mutatie
Adapt Alec
1e en 2e lijn | III-IV | ALK mutatie

